Clinical Trials
39 trialsImmunoPET With an Anti-CD8 Imaging Agent
University Medical Center Groningen
CELEBRATE
Peter MacCallum Cancer Centre, Australia
CRLM-Z
University Hospital, Linkoeping
A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents
OncoResponse, Inc.
MSCs for the Treatment of Burn Wounds
Instituto Venezolano de Investigaciones Cientificas
HLX301
Shanghai Henlius Biotech
A Study of Orally Administered JBI-802, an LSD1/HDAC6 Inhibitor, in Patients With Advanced Solid Tumors
Jubilant Therapeutics Inc.
A Dose Escalation With Expansion Study of EMB-01 in Participants With Advanced/Metastatic Solid Tumors
Shanghai EpimAb Biotherapeutics Co., Ltd.
SeliGIST
Grupo Espanol de Investigacion en Sarcomas
REGOMUNE
Institut Bergonié
The Phase I/Phase II Clinical Study of VC004 in Patients With Localized Advanced/Metastatic Solid Tumors
Jiangsu vcare pharmaceutical technology co., LTD
A Phase I/II Dose Escalation Study of the Tumor-targeting Human L19-IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Dacarbazine for Patients With Metastatic Melanoma
Philogen S.p.A.
A Phase 2 Trial of SCO-101 in Combination With FOLFIRI for Patients With Metastatic Colorectal Cancer (mCRC) With Acquired Resistance to FOLFIRI
Scandion Oncology A/S
NeoPepVac
Herlev Hospital
PULSE-UM
Institut d'Investigació Biomèdica de Bellvitge
A Study of CN202 in Adult Subjects With Locally Advanced or Metastatic Solid Tumors or Hematologic Malignancies
Curon Biopharmaceutical (Australia) Co Pty Ltd
An Open-label, Phase I/II Study of Manganese Plus Radiotherapy in Patients With Metastatic Solid Tumors or Lymphoma
Chinese PLA General Hospital
An Open-label, Phase I/II Study of the Pan-immunotherapy in Patients With Local Advanced/Metastatic Pancreatic Cancer
Chinese PLA General Hospital
Microwave Ablation of Primary and Secondary Lung Malignancies
University of Calgary
Study of SHR2150 (TLR7 Agonist) in Combination With Chemotherapy Plus PD-1 or CD47 Antibody in Subjects With Unresectable/ Metastatic Solid Tumors
Chinese PLA General Hospital
DEBOXA for Inoperable NET Liver Metastases
Xiangya Hospital of Central South University
A Phase I/II Study of XELOXIRI and Bevacizumab as First-line Treatment in Metastatic Colorectal Cancer
ChineseAMS
A Phase I/II Study of the Pan-immunotherapy in Patients With Local Advanced/Metastatic BTC
Chinese PLA General Hospital
Anlotinib and Irinotecan for Ewing Sarcoma
Peking University People's Hospital
PI-MMC
Peking University First Hospital
Evaluation of Viatarâ„¢ Oncopheresis System in Removing CTC From Whole Blood
Viatar LLC
ADSCs-BWs
A.A. Partners, LLC
Radical Surgery Followed by Immunotherapy Using Precision T Cells Specific to Multiple Common Tumor-Associated Antigen for the Treatment of Hepatocellular Carcinoma
Second Military Medical University
Cyclophosphamide, Radiation Therapy, and Poly ICLC in Treating Patients With Unresectable, Recurrent, Primary, or Metastatic Liver Cancer
Rutgers, The State University of New Jersey
Radiation Therapy in Treating Patients Who Are Undergoing Surgery to Remove a Metastatic Brain Tumor
National Cancer Institute (NCI)
Carmustine Followed By Surgery in Treating Patients With Recurrent Supratentorial Malignant Glioma or Metastatic Brain Neoplasm
National Cancer Institute (NCI)
Magnetic Resonance Imaging-Guided Laser Induced Thermal Therapy for Treatment of Metastatic Brain Tumors
Visualase, Inc.
GVAX in Advanced Prostate Cancer Patients Made Lymphopenic
Providence Health & Services
A Study of Picoplatin and Docetaxel in Subjects With Prostate Cancer
Poniard Pharmaceuticals
Combined Treatment of Cetuximab and Paclitaxel in Basal Like Breast Carcinoma
Hadassah Medical Organization
Tolerance and Pharmacokinetics With Capecitabine 5 Out of 7 Days Regimen
Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie
Inhaled Doxorubicin Plus IV Docetaxel and Cisplatin in Patients With Non-Small-Cell Lung Carcinoma (NSCLC)
Zivena
Aroplatin and Capecitabine in Patients With Advanced Colorectal Cancer Resistant to Standard Therapies
Aronex Pharmaceuticals
Aroplatin and Gemcitabine in Patients With Advanced Pancreatic Cancer Resistant to Standard Therapies
Aronex Pharmaceuticals